Dapagliflozin (BMS/AstraZeneca)+ Insulin study in Type 1 Diabetes

AstraZeneca and BMS announced results from a two-week Phase IIa pilot study evaluating dapagliflozin added to insulin in 70 adult patients with sub-optimally controlled Type 1 Diabetes.

Results from this study showed that in patients treated with dapagliflozin, no subjects discontinued due to lack of glycemic control, few genital and urinary tract infections were reported and hypoglycemia was observed in all treatment groups. In addition, mean daily blood glucose derived from 7-point glucose measurements trended downward in all treatment groups through day seven and reductions in total daily insulin dosing at day seven were observed with dapagliflozin. These findings were presented Sunday, June 23, in a late-breaking poster session at the 73rd Scientific Sessions of the American Diabetes Association in Chicago.